Stem cell treatments in china: Rethinking the patient role in the global bio‐economy
Bioethics 27 (4):194-207 (2013)
| Abstract | The paper looks in detail at patients that were treated at one of the most discussed companies operating in the field of untried stem cell treatments, Beike Biotech of Shenzhen, China. Our data show that patients who had been treated at Beike Biotech view themselves as proactively pursuing treatment choices that are not available in their home countries. These patients typically come from a broad variety of countries: China, the United Kingdom, the United States, South Africa and Australia. Among the patients we interviewed there seemed to be both an awareness of the general risks involved in such experimental treatments and a readiness to accept those risks weighed against the possible benefits. We interpret this evidence as possibly reflecting the emergence of risk-taking patients as ‘consumers’ of medical options as well as the drive of patients to seek treatment options in the global arena, rather than being hindered by the ethical and regulatory constraints of their home countries. Further, we found that these patients tend to operate in more or less stable networks and groups in which they interact and cooperate closely and develop opinions and assessments of available treatment options for their ailments. These patients also perform a multiple role as patients, research subjects, and research funders because they are required to pay their way into treatment and research activities. This new social dynamics of patienthood has important implications for the ethical governance of stem cell treatments | |||||||||
| Keywords | ethics of stem cell research patients China translational medicine stem cell tourism | |||||||||
| Categories | ||||||||||
| Options |
|
|||||||||
Download options| PhilPapers Archive |
Upload a copy of this paper Check publisher's policy on self-archival Papers currently archived: 5,653 |
| External links |
 |
| Through your library | Configure |
Similar books and articlesAaron D. Levine & Leslie E. Wolf (2012). The Roles and Responsibilities of Physicians in Patients' Decisions About Unproven Stem Cell Therapies. Journal of Law, Medicine and Ethics 40 (1):122-134.
Edna F. Einsiedel & Hannah Adamson (2012). Stem Cell Tourism and Future Stem Cell Tourists: Policy and Ethical Implications. Developing World Bioethics 12 (1):35-44.
Nikolaus Knoepffler (2004). Stem Cell Research: An Ethical Evaluation of Policy Options. Kennedy Institute of Ethics Journal 14 (1):55-74.
Cynthia B. Cohen Peter J. Cohen (2010). International Stem Cell Tourism and the Need for Effective Regulation: Part II: Developing Sound Oversight Measures and Effective Patient Support. Kennedy Institute of Ethics Journal 20 (3):207-230.
Mark T. Brown (2009). Moral Complicity in Induced Pluripotent Stem Cell Research. Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Richard M. Doerflinger (1999). The Ethics of Funding Embryonic Stem Cell Research: A Catholic Viewpoint. Kennedy Institute of Ethics Journal 9 (2):137-150.
Frederic Bretzner, Frederic Gilbert, Françoise Baylis & Robert M. Brownstone (2011). Target Populations for First-In-Human Embryonic Stem Cell Research in Spinal Cord Injury. Cell Stem Cell 8 (5):468-475.
Insoo Hyun (2010). Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges. Journal of Law, Medicine and Ethics 38 (2):277-285.
Carolyn Mcleod & Françoise Baylis (2007). Donating Fresh Versus Frozen Embryos to Stem Cell Research: In Whose Interests? Bioethics 21 (9):465–477.
David Magnus (2010). Translating Stem Cell Research: Challenges at the Research Frontier. Journal of Law, Medicine and Ethics 38 (2):267-276.
Glenn McGee & Arthur L. Caplan (1999). The Ethics and Politics of Small Sacrifices in Stem Cell Research. Kennedy Institute of Ethics Journal 9 (2):151-158.
Cynthia B. Cohen Peter J. Cohen (2010). International Stem Cell Tourism and the Need for Effective Regulation: Part I: Stem Cell Tourism in Russia and India: Clinical Research, Innovative Treatment, or Unproven Hype? Kennedy Institute of Ethics Journal 20 (1):pp. 27-49.
Tamra Lysaght & Alastair V. Campbell (2013). Broadening the Scope of Debates Around Stem Cell Research. Bioethics 27 (5):251-256.
Zubin Master & G. K. D. Crozier (2012). The Ethics of Moral Compromise for Stem Cell Research Policy. Health Care Analysis 20 (1):50-65.
Analytics
Monthly downloads |
Added to index2011-11-18Total downloads9 ( #113,941 of 548,984 )Recent downloads (6 months)2 ( #37,320 of 548,984 )How can I increase my downloads? |
My notes
Discussion
